Comparison of Efficacy in Removal of Advanced Glycation End Products (AGEs) Between Super High-flux Hemodialysis and Postdilution Online Hemodiafiltration: A Single-center, Prospective, Open-label, Crossover Randomized Controlled Trial
- Disease/Condition
- End Stage Renal Disease
- Drug/Device/Intervention
- super high-flux hemodialysis
- Study type
- Interventional
- Intervention type
- device
- Primary sponsor
- Mahidol University
- Location
- Phaya Thai, Thailand
- Phase
- N/A
- Start date
- Apr 04, 2022
- End date
- Jun 30, 2023
- Enrollment
- 22 participants
skin autofluorescence for AGEs
The goal of this clinical trial is to compare efficacy in advanced glycation end products
 removal between Super high-flux Hemodialysis and high-volume post-dilution online
 hemodiafiltration. The main question it aims to answer are
 
 - Efficacy : endothelial dysfunction biomarker (AGEs) in super high-flux hemodialysis
 compared to online HDF
 
 - Safety profile : Dialysate albumin loss, Intradialytic complication
 
 Participants will be asked to randomized in 2 groups : Super high-flux HD or post dilution
 ol-HDF Researchers will compare SHF-HD and ol-HDF to see whether SHF-HD could remove AGEs
 better than ol-HDF
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05777148
- Type
- Device Trial
Access comprehensive clinical trial information for NCT05777148 through Pure Global AI's free database. This phase not specified trial is sponsored by Mahidol University and is currently Not yet recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 22 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.